Clinical Trial

Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)

Study acronym: SeliSarc
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 25, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Phase I-II, non-randomized, single-arm, open-label, multicenter, international clinical trial. Patients with advanced soft-tissue sarcoma (leiomyosarcoma or malignant peripheral nerve sheath tumor) will receive selinexor in combination with gemcitabine.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-27.
Trial Details
NCT Number NCT06114004
Lead Sponsor Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Conditions Sarcoma,Soft Tissue
Enrollment 88 participants
Start Date 2023-09-28
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-25